Anti-TNF therapy appears effective after first-line Entyvio in IBD

SAN ANTONIO — In patients with inflammatory bowel disease, first-line vedolizumab treatment did not appear to compromise the effectiveness of successive anti-TNF treatment in real-world practice, according to findings presented at the American College of Gastroenterology Annual Meeting.
These results offer a better understanding of the clinical effectiveness of second-line anti-TNF treatment following Entyvio (vedolizumab, Takeda); however, larger studies with longer follow up are needed, according to Andres Yarur, MD, assistant professor of medicine at the Medical College of Wisconsin.

Source link

Related posts

Lupus and the Microbiome


Cover 1


Treating HCV in prison ‘microenvironment’ reduces transmission


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy